

Hikaru Hori

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1523039/publications.pdf>

Version: 2024-02-01

122
papers

2,508
citations

186265

28
h-index

254184

43
g-index

127
all docs

127
docs citations

127
times ranked

3475
citing authors

#	ARTICLE	IF	CITATIONS
1	Elderly bipolar disorder with hyperthyroidism during long-term lithium treatment: A case report. <i>Bipolar Disorders</i> , 2022, 24, 90-90.	1.9	2
2	Hypnotic medication use among inpatients with schizophrenia and major depressive disorder: results of a nationwide study. <i>Sleep Medicine</i> , 2022, 89, 23-30.	1.6	16
3	Association between the examination rate of treatment-resistant schizophrenia and the clozapine prescription rate in a nationwide dissemination and implementation study. <i>Neuropsychopharmacology Reports</i> , 2022, 42, 3-9.	2.3	14
4	The characteristics of patients receiving psychotropic pro re nata medication at discharge for the treatment of schizophrenia and major depressive disorder: A nationwide survey from the EGUIDE project. <i>Asian Journal of Psychiatry</i> , 2022, 69, 103007.	2.0	12
5	Successful treatment for major depressive disorder with psychotic features with addition of asenapine on escitalopram. <i>Psychogeriatrics</i> , 2022, 22, 413-414.	1.2	0
6	Subjective assessment of participants in education programs on clinical practice guidelines in the field of psychiatry. <i>Neuropsychopharmacology Reports</i> , 2022, 42, 221-225.	2.3	12
7	Pre-treatment plasma cytokine levels as potential predictors of short-term remission of depression. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 785-793.	2.6	6
8	A dissemination and education programme to improve the clinical behaviours of psychiatrists in accordance with treatment guidelines for schizophrenia and major depressive disorders: the Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE) project. <i>BIPsych Open</i> , 2022, 8, e83.	0.7	11
9	Prescription of Anticholinergic Drugs in Patients With Schizophrenia: Analysis of Antipsychotic Prescription Patterns and Hospital Characteristics. <i>Frontiers in Psychiatry</i> , 2022, 13, .	2.6	9
10	Clozapine Treatment Is Associated With Higher Prescription Rate of Antipsychotic Monotherapy and Lower Prescription Rate of Other Concomitant Psychotropics: A Real-World Nationwide Study. <i>International Journal of Neuropsychopharmacology</i> , 2022, 25, 818-826.	2.1	11
11	Effects of the number of hospitalizations on cognitive function in Japanese patients with stable schizophrenia. <i>CNS Spectrums</i> , 2021, 26, 658-663.	1.2	6
12	Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. <i>Molecular Psychiatry</i> , 2021, 26, 118-133.	7.9	71
13	Improvements in the degree of understanding the treatment guidelines for schizophrenia and major depressive disorder in a nationwide dissemination and implementation study. <i>Neuropsychopharmacology Reports</i> , 2021, 41, 199-206.	2.3	17
14	Editorial: How to Help Employees Returning to Work Following Depression. <i>Frontiers in Psychiatry</i> , 2021, 12, 714589.	2.6	1
15	Psychological training to improve psychosocial function in patients with major depressive disorder: A randomised clinical trial. <i>Psychiatry Research</i> , 2021, 300, 113906.	3.3	8
16	Prospects for CNPT. <i>Clinical Neuropsychopharmacology and Therapeutics</i> , 2021, 12, 11-11.	0.3	1
17	Pharmacological treatment algorithms for the acute phase, agitation, and maintenance phase of first-episode schizophrenia: Japanese Society of Clinical Neuropsychopharmacology treatment algorithms. <i>Human Psychopharmacology</i> , 2021, 36, e2804.	1.5	5
18	Doxazosin improved COVID-19 associated nightmare in a patient with major depressive disorder: a case report with a positive rechallenge. <i>International Clinical Psychopharmacology</i> , 2021, 36, 221-223.	1.7	1

#	ARTICLE	IF	CITATIONS
19	Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment project. <i>Asian Journal of Psychiatry</i> , 2021, 63, 102744.	2.0	28
20	No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial. <i>European Neuropsychopharmacology</i> , 2021, 53, 34-46.	0.7	22
21	Plasma levels of 3-methoxy-4-hydroxyphenylglycol levels, number of hospitalization and cognitive function predicts the cognitive effect of atypical antipsychotic monotherapy in patients with acute schizophrenia. <i>International Clinical Psychopharmacology</i> , 2020, 35, 89-97.	1.7	4
22	Unmet needs of patients with major depressive disorder â€” Findings from the â€”Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)â€” project: A nationwide dissemination, education, and evaluation study. <i>Psychiatry and Clinical Neurosciences</i> , 2020, 74, 667-669.	1.8	20
23	Predictors of return to work success among Japanese employees with major depressive disorder. <i>Psychiatry Research</i> , 2020, 291, 113209.	3.3	3
24	Exploratory study of association between blood immune markers and cognitive symptom severity in major depressive disorder: Stratification by body mass index status. <i>Brain, Behavior, and Immunity</i> , 2020, 88, 242-251.	4.1	10
25	Prescription patterns in patients with schizophrenia in Japan: Firstâ€”quality indicator data from the survey of â€”Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)â€”project. <i>Neuropsychopharmacology Reports</i> , 2020, 40, 281-286.	2.3	32
26	<p>Assessment of current clinical practices for major depression in Japan using a web-based questionnaire</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 2821-2832.	2.2	3
27	Improvement of psychiatristsâ€™ clinical knowledge of the treatment guidelines for schizophrenia and major depressive disorders using the â€”Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)â€” project: A nationwide dissemination, education, and evaluation study. <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 642-648.	1.8	35
28	Risk factors for further sick leave among Japanese workers returning to work after an episode of major depressive disorder: a prospective follow-up study over 1 year. <i>BMJ Open</i> , 2019, 9, e029705.	1.9	14
29	Deciphering reward-based decision-making in schizophrenia: A meta-analysis and behavioral modeling of the Iowa Gambling Task. <i>Schizophrenia Research</i> , 2019, 204, 7-15.	2.0	23
30	Efficacy, Tolerability, and Safety of Blonanserin in Schizophrenia: An Updated and Extended Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Pharmacopsychiatry</i> , 2019, 52, 52-62.	3.3	22
31	Immunoglobulin genotypes and cognitive functions in schizophrenia. <i>Immunogenetics</i> , 2018, 70, 67-72.	2.4	6
32	Effect of single caffeine intake on neuropsychological functions in healthy volunteers: A double-blind placebo-controlled study. <i>PLoS ONE</i> , 2018, 13, e0202247.	2.5	13
33	Effects of Continuing Oral Risperidone vs. Switching from Risperidone to Risperidone Long-Acting Injection on Cognitive Function in Stable Schizophrenia Patients: A Pilot Study. <i>Frontiers in Psychiatry</i> , 2018, 9, 74.	2.6	12
34	The Impact of Aging, Psychotic Symptoms, Medication, and Brain-Derived Neurotrophic Factor on Cognitive Impairment in Japanese Chronic Schizophrenia Patients. <i>Frontiers in Psychiatry</i> , 2018, 9, 232.	2.6	14
35	Social cognition and metacognition contribute to accuracy for self-evaluation of real-world functioning in patients with schizophrenia. <i>Schizophrenia Research</i> , 2018, 202, 426-428.	2.0	7
36	Cognitive Deficits in the THINC-Integrated Tool (THINC-it) Are Associated With Psychosocial Dysfunction in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2018, 80, .	2.2	14

#	ARTICLE	IF	CITATIONS
37	Relationship between the hippocampal shape abnormality and serum cortisol levels in first-episode and drug-naïve major depressive disorder patients. <i>Depression and Anxiety</i> , 2017, 34, 401-409.	4.1	21
38	The Contactless Vital Sensing System Precisely Reflects R-R Interval in Electrocardiograms of Healthy Subjects. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2017, 40, 514-515.	1.2	6
39	The Nursing Assessment of Medication Acceptance: the reliability and validity of a schizophrenia medication adherence scale. <i>Therapeutic Advances in Psychopharmacology</i> , 2017, 7, 11-16.	2.7	1
40	Relationships between serum brain-derived neurotrophic factor, plasma catecholamine metabolites, cytokines, cognitive function and clinical symptoms in Japanese patients with chronic schizophrenia treated with atypical antipsychotic monotherapy. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 401-408.	2.6	34
41	Blood Biomarkers Predict the Cognitive Effects of Aripiprazole in Patients with Acute Schizophrenia. <i>International Journal of Molecular Sciences</i> , 2017, 18, 568.	4.1	12
42	Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 437-441.	2.2	8
43	Marked Improvement of Meige Syndrome in a Japanese Male Patient with Schizophrenia After Switching from Risperidone to Paliperidone: A Case Report. <i>Journal of UOEH</i> , 2016, 38, 233-236.	0.6	7
44	Adding metoclopramide to paroxetine induced extrapyramidal symptoms and hyperprolactinemia in a depressed woman: a case report. <i>Neuropsychiatric Disease and Treatment</i> , 2016, Volume 12, 2279-2281.	2.2	5
45	Relationship between G1287A of the NET Gene Polymorphisms and Brain Volume in Major Depressive Disorder: A Voxel-Based MRI Study. <i>PLoS ONE</i> , 2016, 11, e0150712.	2.5	18
46	Decreased Activity at the Time of Return to Work Predicts Repeated Sick Leave in Depressed Japanese Patients. <i>Journal of Occupational and Environmental Medicine</i> , 2016, 58, e56-e57.	1.7	3
47	Cognitive insight and functional outcome in schizophrenia; a multi-center collaborative study with the specific level of functioning scale—Japanese version. <i>Schizophrenia Research: Cognition</i> , 2016, 6, 9-14.	1.3	30
48	Does subjective sleep quality improve by a walking intervention? A real-world study in a Japanese workplace. <i>BMJ Open</i> , 2016, 6, e011055.	1.9	22
49	Serum levels of brain-derived neurotrophic factor (BDNF), proBDNF and plasma 3-methoxy-4-hydroxyphenylglycol levels in chronic schizophrenia. <i>Annals of General Psychiatry</i> , 2016, 15, 1.	2.7	13
50	Electroconvulsive therapy-associated neutropenia in treatment-resistant schizophrenia: Three case reports. <i>Psychiatry and Clinical Neurosciences</i> , 2015, 69, 504-504.	1.8	1
51	Catechol-O-methyltransferase Val158Met genotype and the clinical responses to duloxetine treatment or plasma levels of 3-methoxy-4-hydroxyphenylglycol and homovanillic acid in Japanese patients with major depressive disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 967.	2.2	7
52	Plasma levels of 3-methoxy-4-hydroxyphenylglycol are associated with microstructural changes within the cerebellum in the early stage of first-episode schizophrenia: a longitudinal VBM study. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 2315.	2.2	9
53	Relationships between brain-derived neurotrophic factor, clinical symptoms, and decision-making in chronic schizophrenia: data from the Iowa Gambling Task. <i>Frontiers in Behavioral Neuroscience</i> , 2014, 8, 417.	2.0	24
54	Effect of blonanserin on cognitive and social function in acute phase Japanese schizophrenia compared with risperidone. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 527.	2.2	28

#	ARTICLE	IF	CITATIONS
55	Hiccups Associated With Switching From Olanzapine to Aripiprazole in a Patient With Paranoid Schizophrenia. <i>Clinical Neuropharmacology</i> , 2014, 37, 88-89.	0.7	14
56	Comparison of lithium, aripiprazole and olanzapine as augmentation to paroxetine for inpatients with major depressive disorder. <i>Therapeutic Advances in Psychopharmacology</i> , 2014, 4, 123-129.	2.7	8
57	A successful case of dose reduction in etizolam dependence using fine granules: a case report. <i>International Medical Case Reports Journal</i> , 2014, 7, 121.	0.8	3
58	Serum proBDNF/BDNF and response to fluvoxamine in drug-naïve first-episode major depressive disorder patients. <i>Annals of General Psychiatry</i> , 2014, 13, 19.	2.7	25
59	No significant association between brain-derived neurotrophic factor gene rs6265 and cognitive function in Japanese patients with schizophrenia. <i>Psychiatry Research</i> , 2014, 215, 803-805.	3.3	3
60	Abnormal White Matter Integrity in the Corpus Callosum among Smokers: Tract-Based Spatial Statistics. <i>PLoS ONE</i> , 2014, 9, e87890.	2.5	35
61	Serum Levels of Brain-Derived Neurotrophic Factor at 4 Weeks and Response to Treatment with SSRIs. <i>Psychiatry Investigation</i> , 2014, 11, 84.	1.6	12
62	Duloxetine, a Selective Noradrenaline Reuptake Inhibitor, Increased Plasma Levels of 3-Methoxy-4-hydroxyphenylglycol but Not Homovanillic Acid in Patients with Major Depressive Disorder. <i>Clinical Psychopharmacology and Neuroscience</i> , 2014, 12, 37-40.	2.0	10
63	Plasma levels of interleukin-6 and selective serotonin reuptake inhibitor response in patients with major depressive disorder. <i>Human Psychopharmacology</i> , 2013, 28, 466-470.	1.5	53
64	Aripiprazole improves various cognitive and behavioral impairments after traumatic brain injury: a case report. <i>General Hospital Psychiatry</i> , 2013, 35, 103.e7-103.e9.	2.4	10
65	Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients. <i>Journal of Psychiatric Research</i> , 2013, 47, 1843-1848.	3.1	34
66	Current smoking rate in patients with psychiatric disorders in Japan: Questionnaire survey. <i>Psychiatry Research</i> , 2013, 210, 268-273.	3.3	3
67	Plasma catecholamine metabolite levels and the activities of psychiatric symptoms in systemic lupus erythematosus. <i>Human Psychopharmacology</i> , 2013, 28, 198-202.	1.5	7
68	Serum Brain-Derived Neurotrophic Factor Levels at 6 Months After Remission Are Not Associated With Subsequent Depressive Episodes. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 142-143.	1.4	2
69	Herbal Medicine (Shakuyaku-kanzo-to) Improves Olanzapine-Associated Hyperprolactinemia. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 122-123.	1.4	5
70	The Effects of a Walking Intervention on Depressive Feelings and Social Adaptation in Healthy Workers. <i>Journal of UOEH</i> , 2013, 35, 1-8.	0.6	8
71	Follow-up Study on Electroconvulsive Therapy in Treatment-resistant Depressed Patients after Remission: A Chart Review. <i>Clinical Psychopharmacology and Neuroscience</i> , 2013, 11, 34-38.	2.0	13
72	Several prescription patterns of antipsychotic drugs influence cognitive functions in Japanese chronic schizophrenia patients. <i>International Journal of Psychiatry in Clinical Practice</i> , 2012, 16, 138-142.	2.4	22

#	ARTICLE	IF	CITATIONS
73	Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD). <i>CNS Spectrums</i> , 2012, 17, 155-163.	1.2	39
74	Plasma Levels of Metabolites of Catecholamine in Nicotine-Dependent Patients Treated With Varenicline. <i>Nicotine and Tobacco Research</i> , 2012, 14, 486-489.	2.6	2
75	Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 39, 355-357.	4.8	21
76	Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2012, 8, 119.	2.2	52
77	The cognitive profile of aripiprazole differs from that of other atypical antipsychotics in schizophrenia patients. <i>Journal of Psychiatric Research</i> , 2012, 46, 757-761.	3.1	34
78	Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients. <i>Human Psychopharmacology</i> , 2012, 27, 33-38.	1.5	34
79	Plasma levels of catecholamine metabolites and serum levels of brain-derived neurotrophic factor in smokers with schizophrenia treated with varenicline: A pilot study. <i>Open Journal of Psychiatry</i> , 2012, 02, 327-334.	0.6	1
80	No Association between the Response to the Addition of an Atypical Antipsychotic Drug to an SSRI or SNRI and the BDNF (Val66Met) Polymorphism in Refractory Major Depressive Disorder in Japanese Patients. <i>Clinical Psychopharmacology and Neuroscience</i> , 2012, 10, 49-53.	2.0	7
81	A case of schizophrenia with Meige syndrome induced by long-term aripiprazole successfully treated with perospirone. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 273.	4.8	4
82	The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 1022-1025.	4.8	59
83	Relationships between stress, social adaptation, personality traits, brain-derived neurotrophic factor and 3-methoxy-4-hydroxyphenylglycol plasma concentrations in employees at a publishing company in Japan. <i>Psychiatry Research</i> , 2011, 186, 326-332.	3.3	29
84	Reliability, validity and clinical utility of a Japanese version of the Social Adaptation Self-evaluation Scale as calibrated using the Beck Depression Inventory. <i>Psychiatry and Clinical Neurosciences</i> , 2011, 65, 624-629.	1.8	24
85	No association between BDNF Val66Met polymorphism and emergence of psychiatric symptoms in systemic lupus erythematosus patients. <i>Human Psychopharmacology</i> , 2011, 26, 348-351.	1.5	2
86	Three polymorphisms of the eNOS gene and plasma levels of metabolites of nitric oxide in depressed Japanese patients: a preliminary report. <i>Human Psychopharmacology</i> , 2011, 26, 531-534.	1.5	14
87	Effect of treatment with atypical drugs for 6 months on brain levels of N-acetyl aspartate or serum levels of brain-derived neurotrophic factor in early-stage first-episode schizophrenia - a preliminary study. <i>Clinical Neuropharmacology and Therapeutics</i> , 2011, 2, 34-42.	0.3	0
88	Nonadherence to Paroxetine. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 82-83.	1.4	4
89	Association between plasma nitric oxide metabolites levels and negative symptoms of schizophrenia: a pilot study. <i>Human Psychopharmacology</i> , 2010, 25, 139-144.	1.5	35
90	Varenicline does not increase serum BDNF levels in patients with nicotine dependence. <i>Human Psychopharmacology</i> , 2010, 25, 276-279.	1.5	17

#	ARTICLE	IF	CITATIONS
91	No difference in adherence to paroxetine between depressed patients with early remission and those with late remission based on monitoring of plasma paroxetine concentrations. <i>Human Psychopharmacology</i> , 2010, 25, 487-490.	1.5	3
92	Plasma levels of brain-derived neurotrophic factor and interleukin-6 in patients with dysthymic disorder: comparison with age- and sex-matched major depressed patients and healthy controls. <i>Human Psychopharmacology</i> , 2010, 25, 566-569.	1.5	27
93	Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism. <i>Journal of Psychopharmacology</i> , 2010, 24, 1764-1771.	4.0	36
94	Serum brain-derived neurotrophic factor levels as a novel biological marker for the activities of psychiatric symptoms in systemic lupus erythematosus. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 121-128.	2.6	18
95	Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 256-261.	2.6	35
96	Gray and white matter volumetric and diffusion tensor imaging (DTI) analyses in the early stage of first-episode schizophrenia. <i>Schizophrenia Research</i> , 2010, 116, 196-203.	2.0	62
97	Adding a low dose atypical antipsychotic drug to an antidepressant induced a rapid increase of plasma brain-derived neurotrophic factor levels in patients with treatment-resistant depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 308-312.	4.8	42
98	No alterations of brain GABA after 6 months of treatment with atypical antipsychotic drugs in early-stage first-episode schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 1480-1483.	4.8	32
99	A close correlation between plasma and serum levels of brain-derived neurotrophic factor (BDNF) in healthy volunteers. <i>International Journal of Psychiatry in Clinical Practice</i> , 2010, 14, 220-222.	2.4	20
100	A case of late-onset Tourette's disorder successfully treated with aripiprazole: View from blood levels of catecholamine metabolites and brain-derived neurotrophic factor (BDNF). <i>World Journal of Biological Psychiatry</i> , 2009, 10, 977-980.	2.6	8
101	Fluctuating plasma levels of the active moiety of risperidone is related to occurrence of extrapyramidal symptoms. <i>International Journal of Psychiatry in Clinical Practice</i> , 2009, 13, 21-24.	2.4	6
102	A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder. <i>World Journal of Biological Psychiatry</i> , 2009, 10, 620-622.	2.6	6
103	Serum levels of brain-derived neurotrophic factor in comorbidity of depression and alcohol dependence. <i>Human Psychopharmacology</i> , 2009, 24, 409-413.	1.5	37
104	Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients. <i>Human Psychopharmacology</i> , 2009, 24, 489-494.	1.5	23
105	Associations between plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPC) and negative symptoms or cognitive impairments in early-stage schizophrenia. <i>Human Psychopharmacology</i> , 2009, 24, 639-645.	1.5	21
106	Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 722-726.	4.8	176
107	Effects of antidepressants on plasma metabolites of nitric oxide in major depressive disorder: Comparison between milnacipran and paroxetine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 1451-1453.	4.8	29
108	Blood levels of catecholamine metabolites and brain-derived neurotrophic factor in a case of Sydenham's chorea. <i>World Journal of Biological Psychiatry</i> , 2009, 10, 248-251.	2.6	4

#	ARTICLE	IF	CITATIONS
109	Olanzapine orally disintegrating tablets (Zyprexa Zydis ^R) rapidly improve excitement components in the acute phase of first-episode schizophrenic patients: An open-label prospective study. <i>World Journal of Biological Psychiatry</i> , 2009, 10, 741-745.	2.6	10
110	Acute risperidone treatment did not increase daily cigarette consumption or plasma levels of cotinine and caffeine: a pilot study. <i>Human Psychopharmacology</i> , 2008, 23, 327-332.	1.5	7
111	Addition of risperidone to sertraline improves sertraline-resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertraline. <i>Human Psychopharmacology</i> , 2008, 23, 707-713.	1.5	15
112	A case of vascular depression associated with musical hallucinations successfully treated with paroxetine and a low dose of risperidone. <i>Psychogeriatrics</i> , 2008, 8, 38-41.	1.2	5
113	Two cases of burning mouth syndrome treated with olanzapine. <i>Psychiatry and Clinical Neurosciences</i> , 2008, 62, 359-361.	1.8	28
114	Stress at work alters serum brain-derived neurotrophic factor (BDNF) levels and plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels in healthy volunteers: BDNF and MHPG as possible biological markers of mental stress?. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 679-685.	4.8	79
115	Efficacy of electroconvulsive therapy is associated with changing blood levels of homovanillic acid and brain-derived neurotrophic factor (BDNF) in refractory depressed patients: A pilot study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1185-1190.	4.8	79
116	Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 1034-1037.	4.8	155
117	Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 1072-1077.	4.8	53
118	Effects of acute paroxetine treatment on the consumption of cigarette smoking and caffeine in depressed patients. <i>Human Psychopharmacology</i> , 2007, 22, 483-490.	1.5	7
119	Therapeutic drug monitoring of plasma fluvoxamine levels for treating bulimia nervosa. <i>Psychiatry and Clinical Neurosciences</i> , 2007, 61, 452-452.	1.8	1
120	Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. <i>International Clinical Psychopharmacology</i> , 2007, 22, 21-7.	1.7	51
121	Effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disorders. <i>Human Psychopharmacology</i> , 2006, 21, 433-438.	1.5	48
122	Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients. <i>World Journal of Biological Psychiatry</i> , 0, , 1-6.	2.6	5